Sanofi (EPA:SAN) received a €95.00 ($110.47) target price from equities researchers at Sanford C. Bernstein in a report released on Tuesday, Borsen Zeitung reports. The brokerage currently has a “buy” rating on the stock. Sanford C. Bernstein’s price target would indicate a potential upside of 10.67% from the company’s current price.
SAN has been the subject of a number of other reports. Goldman Sachs Group set a €95.00 ($110.47) price objective on shares of Sanofi and gave the company a “neutral” rating in a research report on Thursday, December 5th. Jefferies Financial Group set a €95.00 ($110.47) target price on Sanofi and gave the company a “buy” rating in a research note on Wednesday, November 27th. HSBC set a €79.00 ($91.86) target price on Sanofi and gave the stock a “neutral” rating in a research report on Wednesday, November 27th. Deutsche Bank set a €92.00 ($106.98) price target on Sanofi and gave the stock a “buy” rating in a research note on Friday, November 1st. Finally, Credit Suisse Group set a €94.00 ($109.30) price target on Sanofi and gave the company a “buy” rating in a report on Friday, November 1st. One analyst has rated the stock with a sell rating, three have assigned a hold rating and nine have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of €89.81 ($104.43).
Sanofi stock opened at €85.84 ($99.81) on Tuesday. Sanofi has a 12-month low of €63.09 ($73.36) and a 12-month high of €92.97 ($108.10). The firm’s fifty day moving average price is €83.29 and its 200 day moving average price is €78.94.
Sanofi Company Profile
Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis.
See Also: What does a market perform rating mean?
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.